US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Veraxa Biotech AG
VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
October 13, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
October 07, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
September 04, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
August 24, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
July 29, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
July 27, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
July 24, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
July 23, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
July 20, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
July 13, 2026
From
Veraxa Biotech AG
Via
GlobeNewswire
Tickers
VRXA
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
May 20, 2025
From
VERAXA Biotech AG
Via
GlobeNewswire
Tickers
VACH
